journal article·2024-08-20Open access

Discovery of a Peptoid-Based Nanoparticle Platform for Therapeutic mRNA Delivery via Diverse Library Clustering and Structural Parametrization

Elizabeth R. Webster, Nicole E. Peck, Juan Diego Echeverri, Shima Gholizadeh, Wei-Lun Tang, Rinette Woo, Anushtha Sharma, Weiqun Liu, Chris S. Rae, Adrienne Sallets, Gowrisudha Adusumilli, Kannan Gunasekaran, Ole A. W. Haabeth, Meredith Leong, Ronald N. Zuckermann, Samuel Deutsch, Colin J. McKinlay

ACS Nano· Volume 18· Issue 33

Abstract

Nanoparticle-mediated mRNA delivery has emerged as a promising therapeutic modality, but its growth is still limited by the discovery and optimization of effective and well-tolerated delivery strategies. Lipid nanoparticles containing charged or ionizable lipids are an emerging standard for in vivo mRNA delivery, so creating facile, tunable strategies to synthesize these key lipid-like molecules is essential to advance the field. Here, we generate a library of N-substituted glycine oligomers, peptoids, and undertake a multistage down-selection process to identify lead candidate peptoids as the ionizable component in our Nutshell nanoparticle platform. First, we identify a promising peptoid structural motif by clustering a library of >200 molecules based on predicted physical properties and evaluate members of each cluster for reporter gene expression in vivo. Then, the lead peptoid motif is optimized using design of experiments methodology to explore variations on the charged and lipophilic portions of the peptoid, facilitating the discovery of trends between structural elements and nanoparticle properties. We further demonstrate that peptoid-based Nutshells leads to expression of therapeutically relevant levels of an anti-respiratory syncytial virus antibody in mice with minimal tolerability concerns or induced immune responses compared to benchmark ionizable lipid, DLin-MC3-DMA. Through this work, we present peptoid-based nanoparticles as a tunable delivery platform that can be optimized toward a range of therapeutic programs.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · RNA and protein synthesis mechanisms

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Nutcracker Therapeutics, 5980 Horton Street Suite 350, Emeryville, California 94608, United States

Molecular Foundry, Lawrence Berkeley National Laboratory, Berkeley, California 94720, United States

References (71)

Show source-provided references
1. 10.1056/NEJMoa203538910.1056/NEJMoa2035389 ↗
2. 10.1056/NEJMoa203457710.1056/NEJMoa2034577 ↗
3. 10.1038/s41587-022-01294-210.1038/s41587-022-01294-2 ↗
4. 10.1038/s41571-023-00811-910.1038/s41571-023-00811-9 ↗
5. 10.1002/adhm.20230240910.1002/adhm.202302409 ↗
6. 10.1021/acs.accounts.1c0055010.1021/acs.accounts.1c00550 ↗
7. 10.1038/natrevmats.2017.5610.1038/natrevmats.2017.56 ↗
8. 10.1021/acs.chemrev.1c0024410.1021/acs.chemrev.1c00244 ↗
9. 10.1016/j.ymthe.2022.07.00710.1016/j.ymthe.2022.07.007 ↗
10. 10.1016/j.ymthe.2019.02.01210.1016/j.ymthe.2019.02.012 ↗
11. 10.1002/jbm.a.3770510.1002/jbm.a.37705 ↗
12. 10.1038/s41467-020-16248-y10.1038/s41467-020-16248-y ↗
13. 10.1038/s41467-023-42672-x10.1038/s41467-023-42672-x ↗
14. 10.1021/jacs.2c0270610.1021/jacs.2c02706 ↗
15. 10.1002/adma.20190257510.1002/adma.201902575 ↗
16. 10.1016/j.biomaterials.2023.12224310.1016/j.biomaterials.2023.122243 ↗
17. 10.1021/jacs.3c0914310.1021/jacs.3c09143 ↗
18. 10.1002/adfm.20191057510.1002/adfm.201910575 ↗
19. 10.1038/s41467-021-27493-010.1038/s41467-021-27493-0 ↗
20. 10.1002/adma.20150582210.1002/adma.201505822 ↗
21. 10.1002/adma.20220962410.1002/adma.202209624 ↗
22. 10.1038/s41587-019-0247-310.1038/s41587-019-0247-3 ↗
23. 10.1038/s41551-021-00786-x10.1038/s41551-021-00786-x ↗
24. 10.1038/s41565-023-01548-310.1038/s41565-023-01548-3 ↗
25. 10.1002/9783527806096.ch710.1002/9783527806096.ch7 ↗
26. 10.1021/ja00052a07610.1021/ja00052a076 ↗
27. 10.1016/bs.mie.2021.04.02210.1016/bs.mie.2021.04.022 ↗
28. 10.1021/acspolymersau.2c0003610.1021/acspolymersau.2c00036 ↗
29. 10.1021/acs.macromol.8b0239010.1021/acs.macromol.8b02390 ↗
30. 10.1038/s41598-019-39042-310.1038/s41598-019-39042-3 ↗
31. 10.1021/acsinfecdis.1c0053610.1021/acsinfecdis.1c00536 ↗
32. 10.1073/pnas.97.24.1300310.1073/pnas.97.24.13003 ↗
33. 10.1073/pnas.121282610910.1073/pnas.1212826109 ↗
34. 10.1039/D3CC01062G10.1039/D3CC01062G ↗
35. 10.1016/S1074-5521(98)90173-910.1016/S1074-5521(98)90173-9 ↗
36. 10.1021/acsanm.0c0183410.1021/acsanm.0c01834 ↗
37. 10.3390/pharmaceutics1508206810.3390/pharmaceutics15082068 ↗
38. 10.1016/j.bioactmat.2024.03.01710.1016/j.bioactmat.2024.03.017 ↗
39. 10.1002/mabi.20140052410.1002/mabi.201400524 ↗
40. 10.1002/mabi.20160015210.1002/mabi.201600152 ↗
41. 10.1021/jacs.3c0190210.1021/jacs.3c01902 ↗
42. 10.1016/j.ejpb.2023.11.02510.1016/j.ejpb.2023.11.025 ↗
43. 10.1016/j.ymthe.2018.03.01010.1016/j.ymthe.2018.03.010 ↗
44. 10.1002/anie.20201392710.1002/anie.202013927 ↗
45. 10.1002/anie.20120326310.1002/anie.201203263 ↗
46. 10.1002/adma.20231202610.1002/adma.202312026 ↗
47. 10.1002/btm2.1055610.1002/btm2.10556 ↗
48. 10.1016/j.ymthe.2019.05.01210.1016/j.ymthe.2019.05.012 ↗
49. 10.1073/pnas.161965311410.1073/pnas.1619653114 ↗
50. 10.1016/j.tips.2021.03.00210.1016/j.tips.2021.03.002 ↗
51. 10.1038/s42003-021-02441-210.1038/s42003-021-02441-2 ↗
52. 10.1038/ncomms527710.1038/ncomms5277 ↗
53. 10.1038/s41565-020-0669-610.1038/s41565-020-0669-6 ↗
54. 10.1073/pnas.210925611810.1073/pnas.2109256118 ↗
55. 10.1021/acs.jmedchem.0c0140710.1021/acs.jmedchem.0c01407 ↗
56. 10.1002/smsc.20220007110.1002/smsc.202200071 ↗
57. 10.1002/smll.20180509710.1002/smll.201805097 ↗
58. 10.1021/acs.nanolett.0c0059610.1021/acs.nanolett.0c00596 ↗
59. 10.1021/acsnano.3c0118610.1021/acsnano.3c01186 ↗
60. 10.1039/D1NA00712B10.1039/D1NA00712B ↗
61. 10.1073/pnas.130652911010.1073/pnas.1306529110 ↗
62. 10.1007/s12016-013-8368-910.1007/s12016-013-8368-9 ↗
63. 10.1080/19420862.2018.143397410.1080/19420862.2018.1433974 ↗
64. 10.1016/j.jmb.2007.02.02410.1016/j.jmb.2007.02.024 ↗
65. 10.1016/j.ijpharm.2021.12058610.1016/j.ijpharm.2021.120586 ↗
66. 10.1021/acsnano.8b0151610.1021/acsnano.8b01516 ↗
67. 10.3390/pharmaceutics1502059710.3390/pharmaceutics15020597 ↗
68. 10.1016/j.jconrel.2021.12.02710.1016/j.jconrel.2021.12.027 ↗
69. 10.1016/j.jconrel.2021.05.02110.1016/j.jconrel.2021.05.021 ↗
70. 10.3390/ph1608108810.3390/ph16081088 ↗
71. 10.1038/s41590-022-01160-y10.1038/s41590-022-01160-y ↗